Phase 4 N=603 Parietex Progrip Study
Hernia, Inguinal
Primary: Pain Assessment During the First Three Months and at One Year After Surgery Using a Visual Analogue Scale (VAS) — 7.48; 6.76; 4.62; 5.27 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=61 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
Uterine Fibroids · Fertility Disorders
Primary: Number of Patients With Adhesions to Uterine Scars — 12; 24 participants
Phase 2 N=35 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Phase 2 N=143 Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
Hepatitis C
Primary: Percentage of Participants With Sustained Viral Response (SVR) 12 Weeks After Completing All Study Therapy (SVR12) — 33.3; 89.3; 80.0; 89.5 Percentage of participants
Phase 2 N=606 Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants — 0.57; 0.65; 0.37; 0.34 AER events/person-year — p=0.781
Phase 4 N=58 Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
Psoriasis
Primary: Physician Global Assessement — 68; 80; 79 percentage of patients
Phase 3 N=413 A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death — 125; 87 participants
Phase 3 N=9 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Chronic Myelogenous Leukemia · Malignant Melanoma · Renal Cell Carcinoma
Primary: Number of Participants With Serious Adverse Events (SAEs) — 1 participants
Phase 3 N=40 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Chronic Hepatitis C · Genotype 4 Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 100 percentage of participants
Phase 3 N=51 Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study
Fibromyalgia
Primary: Change From Baseline in Weekly Average Pain Score on the Visual Analog Scale at Week 10 — -1.33; -1.54 units on a scale
Phase 4 N=25 Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease
End Stage Renal Disease
Primary: Change From Baseline in Antibody Concentrations After 13-valent Conjugate Pneumococcal Vaccination in in Patients 50 Years or Older With End Stage Renal Disease on…
Phase 3 N=562 Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain
Pain, Postoperative · Tooth Diseases
Primary: Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h) — 10.554; 15.824; 40.165; 52.291 units on a scale — p=<0.0001
Phase 1 N=36 Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate
Healthy
Primary: AUC(0-tz) — 133; 124; 122 μg*h/mL
N/A N=22 Investigation of the Efficacy of tDCS in the Treatment of Complex Regional Pain Syndrome (CRPS) Type 1
Reflex Sympathetic Dystrophy
Primary: Pain Severity — 22.18; 23.36; 18.00; 23.82 units on a scale — p=0.065
N/A N=40 Ultrasound in Muscle Biopsy
Myopathy · Myositis · Muscular Dystrophy
Primary: Amount of Tissue Obtained — 0.29; 0.28 grams